Surf Bio

Executive Summary

Surf Bio is a preclinical biopharmaceutical company leveraging its proprietary Surf SnapShot™ platform to enable ultra-high concentration formulations of monoclonal antibodies and other biologics. This breakthrough allows large therapeutic doses to be delivered via a single, rapid subcutaneous injection, potentially replacing lengthy intravenous infusions. Founded in 2021 and headquartered in San Diego, the company initially targets high-value indications such as diabetes, oncology, HIV, and COVID-19. By addressing key limitations in biologic delivery—namely, the need for high-concentration formulations for subcutaneous administration—Surf Bio's platform could significantly improve patient convenience, reduce healthcare costs, and expand access to biologic therapies. Although still in preclinical stages, the technology has the potential to disrupt the drug delivery landscape, particularly for chronic diseases requiring frequent dosing. The company's near-term focus is on generating compelling preclinical proof-of-concept data to support further development and attract strategic partnerships. Success will depend on demonstrating the platform's safety, efficacy, and scalability in animal models, as well as navigating the challenging regulatory path for novel delivery technologies. With a strong value proposition and addressing a clear unmet need, Surf Bio represents an early-stage investment opportunity with high-risk, high-reward potential.

Upcoming Catalysts (preview)

• Q3 2026Preclinical proof-of-concept data readout in lead indication60% success
• Q1 2027Series A financing round50% success
• Q4 2026Initiation of IND-enabling studies55% success